711 related articles for article (PubMed ID: 10794299)
1. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
Yang Y; Li Q; Miyashita H; Howlett W; Siddiqui M; Shuaib A
J Neurosurg; 2000 May; 92(5):841-7. PubMed ID: 10794299
[TBL] [Abstract][Full Text] [Related]
2. Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Yang Y; Li Q; Shuaib A
Neuropharmacology; 2000 Mar; 39(5):881-8. PubMed ID: 10699454
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase.
Shuaib A; Yang Y; Li Q
Exp Neurol; 2000 Feb; 161(2):733-9. PubMed ID: 10686092
[TBL] [Abstract][Full Text] [Related]
4. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
Zhang L; Zhang ZG; Zhang RL; Lu M; Krams M; Chopp M
Stroke; 2003 Jul; 34(7):1790-5. PubMed ID: 12805500
[TBL] [Abstract][Full Text] [Related]
5. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
Yang Y; Li Q; Yang T; Hussain M; Shuaib A
J Neurosurg; 2003 Feb; 98(2):397-403. PubMed ID: 12593629
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy.
Shuaib A; Yang Y; Nakada MT; Li Q; Yang T
J Cereb Blood Flow Metab; 2002 Feb; 22(2):215-22. PubMed ID: 11823719
[TBL] [Abstract][Full Text] [Related]
7. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
del Zoppo GJ; Higashida RT; Furlan AJ; Pessin MS; Rowley HA; Gent M
Stroke; 1998 Jan; 29(1):4-11. PubMed ID: 9445320
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia.
Yang Y; Li Q; Shuaib A
Exp Neurol; 2000 May; 163(1):39-45. PubMed ID: 10785442
[TBL] [Abstract][Full Text] [Related]
9. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.
Zhang L; Zhang ZG; Zhang RL; Lu M; Adams J; Elliott PJ; Chopp M
Stroke; 2001 Dec; 32(12):2926-31. PubMed ID: 11739997
[TBL] [Abstract][Full Text] [Related]
10. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model.
Shuaib A; Xu Wang C; Yang T; Noor R
Stroke; 2002 Dec; 33(12):3033-7. PubMed ID: 12468809
[TBL] [Abstract][Full Text] [Related]
11. Multivariable analysis of predictive factors related to outcome at 6 months after intra-arterial thrombolysis for acute ischemic stroke.
Ueda T; Sakaki S; Kumon Y; Ohta S
Stroke; 1999 Nov; 30(11):2360-5. PubMed ID: 10548671
[TBL] [Abstract][Full Text] [Related]
12. Intraarterial urokinase produces significant attenuation of infarction volume in an embolic focal ischemia model.
Shuaib A; Yang Y; Li Q; Siddiqui MM; Kalra J
Exp Neurol; 1998 Dec; 154(2):330-5. PubMed ID: 9878171
[TBL] [Abstract][Full Text] [Related]
13. Hyperacute stroke therapy with tissue plasminogen activator.
Alberts MJ
Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
15. Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model.
Lu HT; Zhao JG; Li MH; Li YD
Brain Res; 2012 Feb; 1438():75-84. PubMed ID: 22227456
[TBL] [Abstract][Full Text] [Related]
16. Effective and safe conditions of low-frequency transcranial ultrasonic thrombolysis for acute ischemic stroke: neurologic and histologic evaluation in a rat middle cerebral artery stroke model.
Saguchi T; Onoue H; Urashima M; Ishibashi T; Abe T; Furuhata H
Stroke; 2008 Mar; 39(3):1007-11. PubMed ID: 18239172
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
Zhang L; Zhang ZG; Buller B; Jiang J; Jiang Y; Zhao D; Liu X; Morris D; Chopp M
Stroke; 2010 May; 41(5):1001-7. PubMed ID: 20203318
[TBL] [Abstract][Full Text] [Related]
18. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Asahi M; Asahi K; Wang X; Lo EH
J Cereb Blood Flow Metab; 2000 Mar; 20(3):452-7. PubMed ID: 10724108
[TBL] [Abstract][Full Text] [Related]
19. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke.
Alonso de Leciñana M; Gutiérrez M; Roda JM; Carceller F; Díez-Tejedor E
J Neurol Sci; 2006 Sep; 247(2):121-9. PubMed ID: 16797595
[TBL] [Abstract][Full Text] [Related]
20. Extension of the thrombolytic time window with minocycline in experimental stroke.
Murata Y; Rosell A; Scannevin RH; Rhodes KJ; Wang X; Lo EH
Stroke; 2008 Dec; 39(12):3372-7. PubMed ID: 18927459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
